Dr. Risa M. Ravitz, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 110
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
NY license 256815
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 110
- Services billed
- 289
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 98 | 65 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 66 | 32 |
| New patient office or other outpatient visit, 45-59 minutes | 66 | 66 |
| Measurement of brain wave activity (eeg), awake and asleep | 40 | 40 |
| Nerve conduction, 13 or more studies | 33 | 32 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in New York, NY | 90 |
| Nortriptyline Hcl Other prescribers in New York, NY | 68 |
| Topiramate Other prescribers in New York, NY | 60 |
| Memantine Hcl Other prescribers in New York, NY | 42 |
| Pregabalin Other prescribers in New York, NY | 38 |
| Nurtec Odt (rimegepant sulfate) Other prescribers in New York, NY | 37 |
| Ubrelvy (ubrogepant) Other prescribers in New York, NY | 26 |
| Emgality Pen (galcanezumab-gnlm) Other prescribers in New York, NY | 26 |
| Aimovig Autoinjector (erenumab-aooe) Other prescribers in New York, NY | 24 |
| Donepezil Hcl Other prescribers in New York, NY | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 52 payments worth $19,257 in total to this clinician.
| AbbVie Inc. | $9,246 |
|---|---|
| Pfizer Inc. | $5,366 |
| Axsome Therapeutics, Inc. | $4,489 |
| Lundbeck LLC | $157 |
| Compensation for services other than consulting (speaking, faculty) | $11,660 |
|---|---|
| Honoraria | $4,313 |
| Consulting Fee | $1,800 |
| Food and Beverage | $1,207 |
| Travel and Lodging | $278 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) UBRELVY · NEUROSCIENCE | $3,800 |
| Pfizer Inc. Mar 7, 2025 | Compensation for services other than consulting (speaking, faculty) ZAVZPRET · PAIN | $3,150 |
| AbbVie Inc. Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $3,000 |
| Pfizer Inc. Sep 22, 2025 | Consulting Fee NURTEC ODT · PAIN | $1,800 |
| Axsome Therapeutics, Inc. Sep 3, 2025 | Honoraria Symbravo · Neurology | $1,725 |
| AbbVie Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $1,710 |
| Axsome Therapeutics, Inc. Aug 13, 2025 | Honoraria Symbravo · Neurology | $1,438 |
| Axsome Therapeutics, Inc. Aug 20, 2025 | Honoraria Symbravo · Neurology | $1,150 |
| AbbVie Inc. Mar 5, 2025 | Travel and Lodging QULIPTA · NEUROSCIENCE · travel to NEW YORK, NY · in-kind | $115 |
| Pfizer Inc. Mar 7, 2025 | Travel and Lodging ZAVZPRET · PAIN · travel to New York, NY · in-kind | $74.61 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $1,710 |
| Pfizer Inc. Sep 22, 2025 | Consulting Fee NURTEC ODT · PAIN | $1,800 |
| Axsome Therapeutics, Inc. Sep 3, 2025 | Honoraria Symbravo · Neurology | $1,725 |
| Axsome Therapeutics, Inc. Sep 3, 2025 | Travel and Lodging Symbravo · Neurology · travel to New York City, NY | $54.81 |
| Axsome Therapeutics, Inc. Sep 3, 2025 | Travel and Lodging Symbravo · Neurology · travel to New York City, NY | $33.28 |
| Axsome Therapeutics, Inc. Aug 20, 2025 | Honoraria Symbravo · Neurology | $1,150 |
| Axsome Therapeutics, Inc. Aug 13, 2025 | Honoraria Symbravo · Neurology | $1,438 |
| AbbVie Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) UBRELVY · NEUROSCIENCE | $3,800 |
| AbbVie Inc. Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $3,000 |
| Pfizer Inc. Mar 7, 2025 | Compensation for services other than consulting (speaking, faculty) ZAVZPRET · PAIN | $3,150 |
| Pfizer Inc. Mar 7, 2025 | Travel and Lodging ZAVZPRET · PAIN · travel to New York, NY · in-kind | $74.61 |
| AbbVie Inc. Mar 5, 2025 | Travel and Lodging QULIPTA · NEUROSCIENCE · travel to NEW YORK, NY · in-kind | $115 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $38,174 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OA…
Amgen Inc. - Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
AbbVie Inc. · Enrolling by invitation · NCT05127954 - Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc. · Recruiting · NCT05125302 - A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie Inc. · Recruiting · NCT05711394 - A phase 4 openlabel study to evaluate the safety and tolerability of daily dosing of rimegepant in episodic migraine prevention
Pfizer Inc. - Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie Inc. - Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06808984 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
AbbVie Inc. · Enrolling by invitation · NCT05707949
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.